On June 10, 2025 Factor Bioscience Inc., a Cambridge-based biotechnology company focused on using its pioneering gene editing platform to develop life-saving cell and gene therapies, reported its participation in the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting to be held in Hong Kong from June 11-14, 2025 (Press release, Factor Bioscience, JUN 10, 2025, View Source [SID1234653805]). Factor will deliver three presentations covering the latest preclinical data from FACT-112, Factor’s engineered iMacrophage program, as well as recent advances in Factor’s gene editing and cell differentiation platforms.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to present the latest data from our engineered iMacrophage program, as well as recent advances in our gene editing and cell differentiation platforms at ISSCR 2025," said Dr. Matt Angel, Co-Founder, Chairman and CEO of Factor. "The data we will be showcasing this week include the first demonstration of targeted delivery of IL-12, a potent immunomodulatory cytokine with established anti-tumor activity, to the solid tumor microenvironment using engineered macrophages. These results represent a major milestone in our work to develop new therapies to treat cancer."

Dr. Kyle Garland, Factor’s Director of Translational Science, added, "After spending more than a decade laying the groundwork by developing cutting-edge RNA-based cell-engineering technologies, Factor is now leveraging these innovative platforms to develop next-generation therapies for patients in need. We are excited to share these remarkable advances in Hong Kong over the next few days."

Details of the presentations are below:

"Hypoimmune iPSC-derived Macrophages Engineered to Express IL-12 Activate Lymphocytes Against Platinum-Resistant Ovarian Cancer." -to be presented by Ian Hay on June 13 from 4:00-5:00 pm HKST, Organ Generation and Regeneration (OGR) and Clinical Applications (CA) Session 3: (Poster Presentation #F1249), Exhibit & Poster Hall (3BCDE, Level 3).

"UltraSlice mRNA Incorporating 5-Methoxyuridine Efficiently Inserts Transgene Sequences in iPSCs with High Viability and Mitigates dsRNA Production." -to be presented by Cassandra Ng on June 12 from 5:00-6:00 pm HKST, Disease Modeling and Drug Discovery (DMDD) Continued, Pluripotency and Development (PD) Session 2: (Poster Presentation #T1348), Exhibit & Poster Hall (3BCDE, Level 3).

"Directed Differentiation of mRNA-Reprogrammed iPSCs via Bioreactors Generates Clinically Relevant Yields of Neural Stem and Progenitor Cells that can be Engineered to Secrete Therapeutic Proteins." -to be presented by Claire Aibel on June 13 from 5:00-6:00 pm HKST, Organ Generation and Regeneration (OGR) and Clinical Applications (CA) Session 3: (Poster Presentation #F1228), Exhibit & Poster Hall (3BCDE, Level 3).
For more information about the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting, visit View Source

About FACT-112
FACT-112 is an mRNA-reprogrammed macrophage engineered using Factor’s patented UltraSlice gene editing platform to deliver IL-12 to solid tumors. Factor is developing FACT-112 for the treatment of platinum-resistant ovarian cancer and other malignant neoplasms.

On June 10, 2025 Adcendo, a clinical-stage biotech company pioneering the development of first and best-in-class ADCs for cancers with a high unmet medical need, reported that the first patient has been dosed in the Phase I/II ADCElerate1 clinical trial evaluating ADCE-D01 in patients with metastatic and/or unresectable soft tissue sarcoma (STS) (Press release, ADCendo, JUN 10, 2025, View Source [SID1234653806]). The patient was dosed at The Memorial Sloan Kettering Cancer Center in New York.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ADCElerate1 (NCT06797999) is a first-in-human Phase I/II multicenter, open-label, dose escalation and expansion study evaluating ADCE-D01 as a monotherapy in patients with metastatic and/or unresectable STS. The primary objective of the study is to evaluate the safety and tolerability of ADCE-D01. The secondary objectives are to characterize the pharmacokinetics and to evaluate the preliminary efficacy of ADCE-D01. The study will recruit in the US and Europe with the European clinical trial application recently approved (EUCT number: 2024-516900-41-00).

Dr. Lone Ottesen, Chief Medical Officer of Adcendo, said: "The dosing of the first patient in the ADCElerate1 study is a major milestone for both Adcendo and for the uPARAP program and we are excited to evaluate ADCE-D01’s potential benefit for patients with advanced STS. uPARAP is a highly attractive target for the development of an ADC in mesenchymal cancers, as it is highly overexpressed in multiple STS subtypes, has unique internalization properties, and shows only very low expression in healthy tissues."

Professor Robert Maki, MD, PhD, Sarcoma Oncologist and Early Drug Development Specialist at the Department Musculoskeletal Cancers and Condition, in the Memorial Sloan Kettering Cancer Center, New York, NY, commented: "We are very pleased to be working with Adcendo to develop ADCE-D01 for the many advanced STS patients who currently have very limited treatment options. ADCs have already made a significant impact across the therapeutic landscape, and we are pleased to be able to bring this exciting treatment modality to our sarcoma patients."

On June 10, 2025 The European Organisation for Research and Treatment of Cancer (EORTC) and Syreon Research Institute reported the official start of DE-ESCALATE, a pragmatic Phase III clinical trial focusing on metastatic prostate cancer (Press release, EORTC, JUN 10, 2025, View Source [SID1234653791]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DE-ESCALATE is one of three research projects coordinated by EORTC, alongside LEGATO and STREXIT-2, which are also funded by the Horizon Europe Programme.

About metastatic prostate cancer
Prostate cancer is the most frequently occurring cancer in men and the third leading cause of cancer death in men.¹ Despite dramatic improvements in early diagnosis and local treatment, one out of five prostate cancer patients will die from their disease.² While data about the rates of metastasis are limited, about 22% of prostate cancer cases metastasize.3 Advanced metastatic prostate cancer is a heterogeneous disease, for which androgen deprivation therapy combined with an androgen receptor pathway inhibitor (ARPI) is the mainstay of treatment.

Metastatic prostate cancer patients suffer from low quality of life and very burdensome symptoms, including treatment-related side effects.

About DE-ESCALATE
The study will evaluate whether intermittent intensified androgen deprivation treatment (iADT) in metastatic prostate cancer is not inferior to continuous treatment in terms of oncological benefit, while minimizing side effects and resource utilization and improving patient quality of life. It is also designed to detect early if iADT has a negative impact on overall survival compared to continuous therapy.

Up to 1,600 patients are expected to be enrolled in this study across Europe. The clinical trial will be opened in 80 sites in the following 8 countries within the EORTC network (Belgium, Croatia, Czechia, Denmark, Italy, Portugal, Romania, Slovenia) and 30 sites across national networks in Ireland, France, and Spain.4
The study is designed with a strong focus on patient centricity, employing a patient-developed health questionnaire to better assess quality of life improvements.

DE-ESCALATE is managed by a multidisciplinary and multistakeholder consortium involving clinical oncologists, surgeons, health economists, and patient representatives.

To compare the effectiveness of the health interventions tested within the study, Syreon Research Institute will deliver a cost-effectiveness analysis and will also oversee the health policy aspects of the dissemination of the study findings.

The DE-ESCALATE study may lead to improved patient survival and quality of life while also improve health system sustainability.

On June 10, 2025 Sanyou Biopharmaceuticals, a leading Shanghai-based high-tech biopharmaceutical company specializing in biologics R&D reported the signing of a strategic cooperation agreement with Medicovestor, Inc., a New York-based biotechnology company pioneering first-in-class chemoimmunotherapy antibody-drug conjugates (ADCs) (Press release, Medicovestor, JUN 10, 2025, View Source [SID1234653807]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The agreement, officially signed on June 6, brings together Medicovestor’s proprietary ADC platforms—ADoBind, a novel dimeric antibody architecture, and ADoTope, a bi-epitope targeting system—with Sanyou’s globally leading AI-STAL (Artificial Intelligence-enabled Super Trillion Antibody Library) technology and intelligent drug screening and preclinical research capabilities. The collaboration aims to accelerate the development of first-in-class chemoimmunotherapies for oncology and autoimmune diseases so that it is "chemoimmunotherapy" ADCs.

Medicovestor is a U.S.-based biotechnology company dedicated to developing next-generation chemoimmunotherapies antibody-drug conjugates (ADCs) for the treatment of cancer and autoimmune diseases. The company has two proprietary technology platforms that enable higher efficacy at lower doses and support combination therapies. Its lead program has entered the IND-enabling stage, with a pancreatic cancer therapy submitted for FDA Orphan Drug Designation. Medicovestor currently holds 11 granted patents and 3 pending applications, positioning the company with a distinct competitive edge in the ADC field.

Dr. Seah Lim, Founder of Medicovestor, has over 25 years of experience in the biopharmaceutical industry and is recognized as a leading global expert in translational medicine. In academia, Dr. Lim has served as a full professor at several prestigious universities in the United Kingdom and the United States, including Brown University and the University of Pittsburgh School of Medicine, where he held multiple leadership positions such as Division Chief. In industry, he has worked as a Product Development Consultant for companies including Bausch Health, Genzyme, and Burroughs Wellcome & Company. He also served as the Pediatric Lead in the Global Program at Sanofi and has held advisory roles such as Independent Director and Commercial & Scientific Advisor at Genie Therapeutics, Inc. Dr. Seah Lim brings not only deep scientific and industry expertise but also extensive clinical experience to the company.

"This partnership reflects our commitment to redefining ADCs by integrating our differentiated ADC platforms with Sanyou’s world-class expertise in antibody development to incorporate immunotherapy into ADCs," said Seah Lim, MD, PhD, Founder and CEO of Medicovestor. "Together, our complementary strengths create a powerful engine to unlock novel therapeutic possibilities for patients with limited treatment options."

"We are excited to collaborate with Medicovestor to realize the promise of their highly innovative chemoimmunotherapy ADC platforms," said David Lang, PhD, Founder and CEO of Sanyou Biopharmaceuticals. "By combining scientific excellence with execution capability, we aim to deliver transformative therapies that change patients’ lives."

The partnership includes joint research, technology transfer, and co-development of lead candidates. Both companies plan to announce development milestones and candidate selections in the coming quarters.

On June 10, 2025 Nantes-based biotech XENOTHERA reported the value of its LIS22 antibody in the treatment of peripheral T-cell lymphomas (PTCL). The PALT1 clinical trial (NCT06495723) has just passed a new milestone at the trial’s scientific committee meeting, confirming continued recruitment (Press release, Xenothera, JUN 10, 2025, View Source [SID1234654024]). Clinical and biological safety, as well as injection tolerance, are encouraging. Preliminary efficacy data, yet to be confirmed, are very encouraging.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To date, 9 patients are participating in the trial. No DLT has been observed, so enrolment at the 6 mg/kg dose is continuing. PALT1 is a Phase I/II trial testing the safety and efficacy of LIS22 in patients with refractory relapsed PTCL. The trial is taking place in France and Italy, with Professor Gandhi Damaj at Caen University Hospital as principal investigator.

The results will be presented orally on Tuesday June 18 at 5:50 p.m. by Firas Bassissi, the biotech’s Scientific Director, at the World Congress on Lymphoma (18th International Conference on Malignant Lymphoma, Lugano, Switzerland, View Source), during the "Experimental Medicines" session under the title "LIS22: An Effective Multimodal Polyclonal Antibody targeting T-Cell Malignancies".

In addition, the PALT1 clinical trial is the subject of an abstract to be published in the proceedings of the same congress (abstract 847: "PALT trial: First in class glyco humanized polyclonal antibody directed against tumoral T cells, in patients with relapsed/refractory peripheral T cells lymphoma (PTCL)").

"To be able to present LIS22 orally and to benefit from an abstract published in the proceedings of the Lugano World Congress is an immense source of pride, and confirms the interest of our treatment, as well as the recognition by the medical and scientific community of the quality and potential of our therapeutic antibody. I am of course delighted to be able to continue this trial, thanks to these results, which are both a validation of our approach and, above all, a source of hope for PTCL patients who have reached a therapeutic impasse. I would like to congratulate the XENOTHERA teams, and above all to thank the patients and medical teams who are working alongside us to analyze the therapeutic potential of LIS22," says Odile Duvaux, President of the biotech company.